"Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome"
"Conclusions and Relevance In patients who experienced an ACS event, direct inhibition of Lp-PLA2with darapladib added to optimal medical therapy and initiated within 30 days of hospitalization did not reduce the risk of major coronary events."
http://jama.jamanetwork.com/article.aspx?articleid=1900827
No comments:
Post a Comment